Suche
Filter by content type
Filter by content year
Filter by category
BioNTech and Fosun Pharma Announce the Start of a Phase 2 Clinical Trial of Lead mRNA COVID-19 Vaccine BNT162b2 in China
November 25, 2020 - … BioNTech and Fosun Pharma Announce the Start of a Phase 2 Clinical Trial … mRNA COVID-19 Vaccine BNT162b2 in China … BioNTech and Fosun Pharma Announce the Start of a Phase 2 Clinical Trial … Lead mRNA COVID-19 Vaccine BNT162b2 in China BioNTech and Fosun Pharma Announce the Start of a Phase 2 Clinical Trial …
BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China
August 5, 2020 - … BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based … COVID-19 Vaccine Candidate in China … BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based … COVID-19 Vaccine Candidate in China BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based …
Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
Juli 20, 2020 - … (excluding China, where BioNTech has a collaboration with Fosun Pharma for BNT162 for both clinical development and … Health, Genentech, a member of the Roche Group, Genevant, Fosun Pharma, and Pfizer. For more information, please visit … between BioNTech and Pfizer, and BioNTech and Fosun Pharma, to develop a potential COVID-19 vaccine; the …
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
Juli 1, 2020 - … (excluding China, where BioNTech has a collaboration with Fosun Pharma for BNT162 for both clinical development and … Health, Genentech, a member of the Roche Group, Genevant, Fosun Pharma, and Pfizer. For more information, please visit … between BioNTech and Pfizer, and BioNTech and Fosun Pharma, to develop a potential COVID-19 vaccine; the …
BioNTech und Fosun Pharma beginnen klinische Studie mit mRNA-basiertem COVID-19-Impfstoffkandidaten in China
August 5, 2020 - … BioNTech und Fosun Pharma beginnen klinische Studie mit mRNA-basiertem … COVID-19-Impfstoffkandidaten in China … BioNTech und Fosun Pharma beginnen klinische Studie mit mRNA-basiertem … COVID-19-Impfstoffkandidaten in China BioNTech und Fosun Pharma beginnen klinische Studie mit mRNA-basiertem …
BioNTech to Present Data from BNT311 (GEN1046) and BNT131 (SAR441000) Programs at SITC 35th Annual Meeting
Oktober 14, 2020 - … Health, Genentech, a member of the Roche Group, Genevant, Fosun Pharma, and Pfizer. For more information, please visit … Health, Genentech, a member of the Roche Group, Genevant, Fosun Pharma, and Pfizer. For more information, please visit … Health, Genentech, a member of the Roche Group, Genevant, Fosun Pharma, and Pfizer. For more information, please visit …
BioNTech to Present New Clinical and Preclinical Data Across Multiple Immuno-Oncology Programs at 36th SITC Annual Meeting
Oktober 1, 2021 - … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit …
BioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma
November 19, 2021 - … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit …
Pfizer and BioNTech Announce New England Journal of Medicine Publication of Phase 1 Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
Oktober 14, 2020 - … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit …
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
Juni 2, 2023 - … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit …